Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.

[1]  T. Hansen,et al.  CRP and suPAR are differently related to anthropometry and subclinical organ damage. , 2013, International journal of cardiology.

[2]  B. Hedblad,et al.  Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. , 2012, Atherosclerosis.

[3]  E. Salido,et al.  Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis , 2011, Nature Medicine.

[4]  J. Laine,et al.  Plasma level of soluble urokinase‐type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study , 2011, Journal of internal medicine.

[5]  M. Pencina,et al.  On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data , 2011, Statistics in medicine.

[6]  T. Hansen,et al.  Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. , 2011, Atherosclerosis.

[7]  H. Lilja,et al.  Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening , 2011, Journal of internal medicine.

[8]  F. Tacke,et al.  Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients , 2011, Critical care.

[9]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[10]  T. Jørgensen,et al.  The cohorts at the Research Centre for Prevention and Health, formerly 'The Glostrup Population Studies'. , 2011, International journal of epidemiology.

[11]  Mei-Jie Zhang,et al.  SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models , 2011, Comput. Methods Programs Biomed..

[12]  L. Manzoli,et al.  Cardiovascular risk of the general population assessed through SCORE and CUORE charts: an extensive survey by the General Practitioners from Abruzzo, Italy. , 2010, International journal of cardiology.

[13]  T. Hansen,et al.  Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population , 2010, Journal of internal medicine.

[14]  B. Fevang,et al.  Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency. , 2009, Clinical immunology.

[15]  Vivian Viallon,et al.  How to evaluate the calibration of a disease risk prediction tool , 2007, Statistics in medicine.

[16]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[17]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[18]  T. Hansen,et al.  C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[19]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[20]  Bernard J. Gersh,et al.  Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention , 2007, Circulation.

[21]  Paul M Ridker,et al.  C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. , 2006, Journal of the American College of Cardiology.

[22]  M. Pencina,et al.  C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. , 2005, Archives of internal medicine.

[23]  C. Schwaenen,et al.  Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[24]  N. Cook,et al.  Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores , 2004, Circulation.

[25]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[26]  M. Osler,et al.  The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. , 2003, Journal of clinical epidemiology.

[27]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[28]  K. Preissner,et al.  Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. , 2002, Blood.

[29]  K. Preissner,et al.  Release of Soluble Urokinase Receptor from Vascular Cells* , 2001, Thrombosis and Haemostasis.

[30]  S. Mustjoki,et al.  Enhanced release of soluble urokinase receptor by endothelial cells in contact with peripheral blood cells , 2000, FEBS letters.

[31]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[32]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[33]  D. Hosmer,et al.  A Simplified Method of Calculating an Overall Goodness-of-Fit Test for the Cox Proportional Hazards Model , 1998, Lifetime data analysis.

[34]  Z. Ying,et al.  Checking the Cox model with cumulative sums of martingale-based residuals , 1993 .